IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Spectrum Pharmaceuticals, Inc. & Advises Investors with...
September 19 2016 - 11:33AM
Business Wire
Lundin Law PC (http://lundinlawpc.com/) announces that it is
investigating claims against Spectrum Pharmaceuticals, Inc.
(“Spectrum” or the “Company”) (Nasdaq: SPPI) concerning possible
violations of federal securities laws.
To get more information about this investigation, please contact
Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via
email at brian@lundinlawpc.com.
The investigation focuses on a statement by Spectrum that it
failed to disclose that the Food & Drug Administration advised
it not to submit a New Drug Application for its drug candidate
apaziquone back in December of 2012.
Lundin Law PC was created by Brian Lundin, a securities
litigator based in Los Angeles.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160919006052/en/
Lundin Law PCBrian Lundin, Esq.Telephone: 888-713-1033Facsimile:
888-713-1125brian@lundinlawpc.comhttp://lundinlawpc.com/
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024